What clinical trials has serlopitant been tested in?
Serlopitant is an investigational drug that has been studied in clinical trials for its effects in conditions involving nausea/vomiting. Trial details and locations (e.g., dosing arms, endpoints, and eligibility criteria) depend on the specific study phase and indication.
Are there any Phase 2 or Phase 3 serlopitant results publicly reported?
Public information on serlopitant trials generally comes from study registrations and sponsor-released materials (or conference abstracts), which can differ by indication and time period. If you share the indication you care about (for example, chemotherapy-induced nausea and vomiting vs. postoperative nausea), I can narrow down the exact trial(s) and reported outcomes that match.
How do serlopitant trials typically measure success?
Clinical trial endpoints for anti-nausea/vomiting agents commonly include measures such as complete response rates (no emesis and/or no rescue medication), nausea severity scores, and the proportion of participants who remain symptom-free over a defined window. The exact endpoint set varies by protocol and indication.
What conditions were serlopitant trials designed to treat?
Trial programs for agents like serlopitant are usually built around specific emetogenic settings (e.g., chemotherapy- or surgery-related). The precise condition(s) studied will determine inclusion criteria (prior antiemetic use, chemotherapy regimen, baseline symptoms) and the planned observation periods.
What are common eligibility criteria in serlopitant studies?
Across antiemetic clinical trials, eligibility often depends on factors such as age, baseline symptom status, planned exposure to a trigger (e.g., chemotherapy or surgery), and whether participants can take standard background antiemetics. Exact criteria are study-specific.
What’s the quickest way to find the right serlopitant trial record?
If you want, tell me:
1) the disease/setting (e.g., “chemotherapy-induced nausea and vomiting”), and
2) whether you want completed results or currently recruiting studies.
With that, I can point you to the most relevant registered trial(s) and summarize the protocol and results tied to serlopitant for that indication.
Where to check serlopitant development and patent context
DrugPatentWatch.com tracks patent and development history for drugs and can be useful for finding which companies and formulations are tied to particular development stages. See: DrugPatentWatch.com.
Sources